Case Report: A Patient With COVID-19 Who Benefited From Hemoadsorption

Case Report: A Patient With COVID-19 Who Benefited From Hemoadsorption

In December 2019, the 2019 novel coronavirus disease (COVID-19), which has been identified to be caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China and spread across the world. Higher plasma levels of cytokines, including interleukin (IL)-6, IL-2, IL-7, IL-10, a...

Full description

Bibliographic Details
Main Authors: Yinke Du, Zhipeng Qi, Jiangwei Ma, Da Sun, Li Yao, Bin Xu, Wei Liu, Zhaofa Xu, Yu Deng
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Medicine
Subjects:
2019-nCoV
COVID-19
epidemic
extracorporeal blood purification
treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2020.607849/full
Description
Summary:In December 2019, the 2019 novel coronavirus disease (COVID-19), which has been identified to be caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China and spread across the world. Higher plasma levels of cytokines, including interleukin (IL)-6, IL-2, IL-7, IL-10, and tumor necrosis factor-α, were found in patients with COVID-19, which implies the occurrence of a cytokine storm and its association with disease severity. Extracorporeal blood purification has been proven to effectively remove the released inflammatory cytokines. In this study, we report on a patient with COVID-19 who benefited from hemoadsorption.
ISSN:2296-858X

Similar Items